

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In reApplication of: BLAZAR, et al.

Application No.: 10/827,023

Group Art Unit: 1636

Filed: 04/19/2004

Examiner: TBA

Title: Regulatory T Cells and Their Use In Immunotherapy and Suppression of

Autoimmune Responses

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail (Label No. EL998810680Us addressed to: Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450, on May 6, 2005	
Date of Deposit	
Debra A. Coccia	
Name Defin A. Cocco 5/6/	/05
Signature Date	

INFORMATION DISCLOSURE UNDER 37 CFR 1.97(b)

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached, if required.

No fee or certification is required in connection with this Information Disclosure, since it is being submitted prior to the last of 1) issuance of a first Office Action on the merits, or 2) expiration of the three-month period following filing of the above-identified application.

It is respectfully requested that the information be considered by the Examiner and that a copy of the attached Form PTO-1449 be returned indicating that such information has been considered.

In the event any fees are required in connection with this paper, please charge Deposit Account No.: 50-0573. A copy of this document is enclosed.

Applicants' undersigned attorney may be reached by telephone at (215) 988-3361 All correspondence should be directed to the below-listed address.

Respectfully submitted,

Dated: May 6, 2005

Evelyn H. McConathy

Registration No. 35,279

DRINKER BIDDLE & REATH LLP

One Logan Square 18th and Cherry Streets

Philadelphia, PA 19103-6996

Tel: (215) 988-3361 Fax: (215) 988-2757 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

A f. C			Application Number	10	0/827,023		
TRANSMITTAL FORM			Filing Date		4/19/2004		
			First Named Inventor	В	LAZAR, et al.		
(to be used for all correspondence after initial filing)		Group Art Unit		636			
, , , , , , , , , , , , , , , , , , , ,			Examiner Name	T	BA		
					2253-76278 [204682]		
Total Number of Pages in T	his Submiss	ion	Attorney Docket Number		* 4		
ENCLOSURES (check all that apply)							
☐ Fee Transmittal Form		☐ Drawing(s) – Figs.		☐ After Allowance Communication			
☐ Fee Attached			•	to	TC		
		Licensin	g-related Papers				
_			5 related 1 apers	☐ Ar	ppeal Communication to		
☐ Amendment/Reply/		☐ Petition		_	oard of Appeals and		
☐ After Final				Interferences			
☐ Affidavits/declaration	on(s)	Petition t	o Convert to a	_{Π Δ} ,	opeal Communication to		
			nal Application	□ Aı TC	-		
Dutanaian af Time D	. aat		• •		opeal Notice, Brief, Reply Brief)		
☐ Extension of Time Requ	iest	D Bower of	Attorney, Revocation	(1)			
			•				
Express Abandonment I	Request	Change of Address	of Correspondence	🗀 Pro	oprietary Information		
* *************************************	1	Address					
				☐ Sta	atus Letter		
■ Information Disclosure Sta	itement	│ ∐ Terminal	Disclaimer				
				_ ^.	Englanda (a)		
П с:с-1 с	4	Request	for Refund		ner Enclosure(s)		
☐ Certified Copy of Priori	ιy	☐ Request for Refund			ease identify below):		
Document(s)	•				449 with (86) cited		
	i	│	nber of CD(s)	referei	nces; Return Postcard.		
Response to Missing Pa	rts/	☐ Landscape Table on CD					
Incomplete Application			oup Table on ob				
Response to Missing							
under 37 CFR 1.52 o	Remarks:		·				
under 3/ CFK 1.32 (и 1.55						
S	IGNATUI	RE OF APPL	ICANT, ATTORNEY, C	R AGI	ENT		
Firm Name		Biddle & Rea					
		16 . A N	. 0				
Signature	H. Mc Con	rathy, 7, Reg No. 35,279					
Printed Name	Printed Name Evelyn H. M						
2701jii in meconacily, regg 110. 35,217							
Date May 6, 2005							
T1 - 1			TE OF EXPRESS MAIL		1.1		
I hereby certify that this paper, along with any documents referred to as being enclosed therewith, is being deposited with the United States Postal Service via express mail label EL998810680US addressed to Mail Stop Amendment,							
May 6, 2005.	i Commiss	noner for Pater	its, P.O. Box 1450, Alexa	naria, V	A 22313-1450 on this date:		
Typed or printed name							
Typed of printed frame							
Signature	1 Dril	nu A. C	scup		Date: May 6, 2005		
421738v1					1 Date Lang of wood		

Sheet 1 of 6 2mr.PTO-1449 DOCKET NO. 22253-76278 APPLN. NO. 10/827,023 **U.S. Department of Commerce** [204682] MAY 0 9 2005 Date Filed: May 6, 2005 APPLICANT: BLAZAR, et al FILING DATE: 04/19/2004 **GROUP 1636 U.S. PATENT DOCUMENTS** Examiner Initial Document Number Date Name Class Subclass Filing Date if appropriate FOREIGN PATENT DOCUMENTS Translation Document Number Country Subclass Yes/No/Abstract OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, etc.) Anasetti C, Martin PJ, Storb R, Appelbaum FR, Beatty PG, Calori E, Davis J, Doney K, Reichert T, Stewart P, et al., "Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3," Bone Marrow Transplant 7:375-381 (1991). Apostolou, I., Sarukhan, A., Klein, L., vonBoehmer, H., "Origin of regulatory T cells with known specificity for antigen," Nat Immunol 3(8):756-763 (2002). Asano M, Toda M, Sakaguchi N, Sakaguchi S, "Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation," J. Exp. Med. 184:387-396 (1996). Asseman, C., Mauze, S., Leach, M.W., Coffman, R.L., Powrie, F., "An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation," J Exp Med 190(7):995-1004 (1999).Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA, "CD4+CD25 high regulatory cells in human peripheral blood," J. Immunol. 167:1245-1253 (2001) Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.J., Pulendran, B., Palucka, K., "Immunobiology of dendritic cells," Annu Rev Immunol 18:767-811 (2000). Belkaid, Y., Piccirillo, C.A., Mendez, S., Shevach, E.M., Sacks, D. L., "CD4+CD25+ regulatory T Cells control Leishmania major persistence and immunity," Nature 420(6915):502-507 (2002). Blaise D, Olive D, Hirn M, Viens P, Lafage M, Attal M, Stoppa AM, Gabert J, Gastaut JA, Camerlo J, et al., "Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients," Bone Marrow Transplant 8:105-111 (1991). Bonomo A, Kehn PJ, Payer E, Rizzo L, Cheever AW, Shevach EM, "Pathogenesis of post-thymectomy autoimmunity. Role of syngeneic MLR- reactive T cells," J. Immunol. 154:6602-6611 (1995). Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J, Lioure B, Michel G, Burdach S, Kolb HJ, et al., "Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study," Transplantation 60:939-942 (1995). Carpenter PA, Pavlovic S, Tso JY, Press OW, Gooley T, Yu XZ, Anasetti C, "Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells," J. Immunol. 165:6205-6213 (2000).

Y	12.	Cella, M., Salio, M., Sakakibara, Y., Langen, H., Julkunen, I., Lanzavecchia, A., "Maturation, activation, and protection of dendritic cells induced by double-stranded RNA," <i>J Exp Med</i> 189(5):821-829 (1999).
	13.	Chai, J.G., Tsang, J.Y., Lechler, R., Simpson, E., Dyson, J., Scott, D., "CD4+CD25+ T Cells as immunoregulatory T cells in vitro," <i>Eur J Immunol</i> 32(8):2365-2375 (2002).
	14.	Chatenoud L, Salomon B, Bluestone JA, "Suppressor T cellsthey're back and critical for regulation of autoimmunity!" <i>Immunol. Rev.</i> 182:149-163 (2001)
	15.	Chen, W., W. Jin, and S. M. Wahl, "Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells," <i>J. Exp. Med.</i> 188:1849-1857 (1998).
	16.	Cohen, J.L., Trenado, A., Vasey, D., Klatzmann, D., Salomon, B.L., "CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease," <i>J Exp Med</i> 196(3):401-406 (2002).
	17.	Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G, "Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood," J. Exp. Med. 193:1303-1310 (2001).
	18.	Dye, E. S. and R. J. North, "T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases," <i>J. Exp. Med.</i> 154:1033-1042 (1981).
•	19.	Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C.G., Strober, S., Negrin, R.S., "CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation," 9(9):1144-1150 (2003).
-	20.	Fukaura, H., S. C. Kent, M. J. Pietrusewicz, S. J. Khoury, H. L. Weiner, and D. A. Hafler, "Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients," <i>J. Clin. Invest.</i> 98:70-77 (1996).
	21.	Gallimore, A., Sakaguchi, S., "Regulation of tumour immunity by CD25+ T cells," <i>Immunology</i> 107(10):5-9 (2002).
	22.	Gao Q, Rouse TM, Kazmerzak K, Field EH, "CD4+CD25+ cells regulate CD8 cell anergy in neonatal tolerant mice," <i>Transplantation</i> 68:1891-1897 (1999).
	23.	Gavin, M., Rudensky, A., "Control of immune homeostasis by Naturally Arising Regulatory CD4+ T Cells," <i>Curr Opin Immunol</i> 15(6):690-696 (2003).
	24.	Godfrey, W.R., Krampf, M.R., Taylor, P.A., Blazar, B.R., "Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation," Blood 103:1158-1165 (February, 2004).
-	25.	Godfrey, W.R., Spoken, D., Ge, Y., Levine, B., June, C., Blazar, B.R., and Porter, S., "In vitro expanded human CD4+CD25+ T regulatory cells can markedly inhibit allogeneic dendritic cell stimulated MLR cultures," <i>Blood</i> 104(2):453-461 (15 July 2004).
	26.	Greenfield, E. A., E. Howard, T. Paradis, K. Nguyen, F. Benazzo, P. McLean, P. Hollsberg, G. Davis, D. A. Hafler, A. H. Sharpe, G. J. Freeman, and V. K. Kuchroo, "B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors," <i>J. Immunol.</i> 158:2025-2034 (1997).

27.	Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG, "A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis," <i>Nature</i> 389:737-42 (1997).
28.	Hall, B.M., Fava, L., Chen, J., Plain, K. M., Boyd, R.A., Spicer, S.T., Berger, M.F., "Anti-CD4 monoclonal antibody-induced tolerance to MHC-incompatible cardiac allografts maintained by CD4+ suppressor T cells that are not dependent upon IL-4," 161(10):5147-5146 (1998).
29.	Hansen, J. A., P. J. Martin, and R. C. Nowinski, "Monoclonal antibodies identifying a novel T-cell antigen and Ia antigens of human lymphocytes," <i>Immunogenetics</i> 10:247-260 (1980).
30.	Hara, M., C. I. Kingsley, M. Niimi, S. Read, S. E. Turvey, A. R. Bushell, P. J. Morris, F. Powrie, and K. J. Wood, "IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo," J. Immunol. 166:3789-3796 (2001).
31.	Harris DT, Sakiestewa D, Lyons C, Kreitman RJ, Pastan I, "Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor," <i>Bone Marrow Transplant</i> 23:137-144 (1999).
32.	Hoffmann, P., Ermann, J., Edinger, M., Fathman, C.B., Strober, S., "Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation," <i>J Exp Med</i> 196(3):389-399 (2002).
33.	Jiang, S., Camara, N., Lombardi, G., Lechler, R.I., "Induction of allopeptide-specific human CD4+CD25+ regulatory T cells <i>ex vivo</i> ," <i>Blood</i> 102(6):2180-2186 (2003).
34.	Jones, S.C., Murphy, G.F., Korngold, R., "Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response," <i>Biol Blood Marrow Transplant</i> 9(4):243-256 (2003).
35.	Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH, "Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells," <i>J. Exp. Med.</i> 196:255-260 (2002)
36.	Jonuleit, H., E. Schmitt, M. Stassen, A. Tuettenberg, J. Knop, and A. H. Enk, "Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood," <i>J. Exp. Med.</i> 193:1285-1294 (2001).
37.	Kung, P., G. Goldstein, E. L. Reinherz, and S. F. Schlossman, "Monoclonal antibodies defining distinctive human T cell surface antigens," <i>Science</i> 206:347-349 (1979).
38.	Laport, G.G., Levine, B.I., Stadmauer, E.A., Schuster, S.J., Luger, S.M., Grupp, S., Bunin, N., Stroble, F.J., Cotte, J., Zheng, Z., Gregson, B., Rivers, P., Vonderheide, R.H., Liebowitz, D.N., Porter, D.L., June, C.H., "Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+ selected hematopoietic cell transplantation," <i>Blood</i> 102(6):2004-2013 (2003).
39.	Lenardo MJ, "Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis," <i>Nature</i> 353:858-861 (1991).
40.	Levine, B.L., Bernstein, W.B., Connors, M., Craighead, N., Lindsten, T., Thompson, C.B., June, C.H., "Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells," <i>J. Immunol.</i> 159(12): 5921-5930 (1997).

_	_	
	41.	Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, Roncarolo MG, "Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells," <i>J. Exp. Med.</i> 196:1335-1346 (2002).
	42.	Levings, M. K., Sangregorio, R., and Roncarolo, M.G., "Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function," <i>J. Exp. Med.</i> 193:1295-1302 (2001).
	43.	Lin, C.H., Hunig, T., "Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist," Eur J. Immunol 33(3):626-638 (2003).
	44.	Lissy NA, Van Dyk LF, Becker-Hapak M, Vocero-Akbani A, Mendler JH, Dowdy SF, "TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point," <i>Immunity</i> 8:57-65 (1998).
	45.	Nakamura K, Kitani A, Strober W, "Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta," <i>J. Exp. Med.</i> 194:629-644 (2001).
	46.	Ng, W.F., Duggan, P.J., Ponchel, F., Matarese, G., Lombardi, G., Edwards, A.D., Isaacs, J.D., Lechler, R.I., "Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells," <i>Blood</i> 98(9):2736-2744 (2001).
	47.	Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R. M. Zinkernagel, "Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction," <i>Nature</i> 411:1058-1064 (2001).
-	48.	Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E, "Tumor rejection by <i>in vivo</i> administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody," <i>Cancer Res.</i> 59:3128-3133 (1999).
	49.	Pasare, C., Medzhitov, R., "Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells," <i>Science</i> (5609):1033-1036 (2003).
	50.	Peng, L., Kjaergaard, J., Plautz, G.E., Awad, M., Drazba, J.A., Shu, S., Cohen, P.A., "Tumor-induced L-selectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy," <i>J. Immunol</i> 169(9): 4811-4821 (2002).
	51.	Piccirillo CA, Shevach EM, "Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells," <i>J. Immunol.</i> 167:1137-1140 (2001).
	52.	Read S, Malmstrom V, Powrie F, "Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation," <i>J. Exp. Med.</i> 192:295-302 (2000).
	53.	S. Sakaguchi, "Naturally arising CD4 regulatory T cells for immunologic self-tolerance and negative control of immune responses," <i>Annu Rev Immunol</i> (2004, published on-line November 17, 2003).
	54.	Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M, "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases." J. Immunol. 155:1151-1164 (1995).
	55.	Sakaguchi, S., N. Sakaguchi, J. Shimizu, S. Yamazaki, T. Sakihama, M. Itoh, Y. Kuniyasu, T. Nomura, M. Toda, and T. Takahashi, "Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance," <i>Immunol. Rev.</i> 182:18-32 (2001).
L		

esentation of soluble antigen by cultured human dendritic age colony-stimulating factor plus interleukin 4 and na," <i>J Exp Med</i> 179(4):1109-1118 (1994). an N, Singh B, Sharpe A, Bluestone JA, "CD28 s of the CD4+CD25+ immunoregulatory T cells that control 0 (2000).
s of the CD4+CD25+ immunoregulatory T cells that control
rells: more questions than answers," Nat. Rev. Immunol.
D4(+)CD25(+) suppressor T cells," J. Exp. Med. 193:F41-F46
mmmunity," Annu. Rev. Immunol. 18:423-449 (2000).
, Thornton, A.M., "Control of T-cell activation by Rev 182:58-67 (2001).
ction of tumor immunity by removing CD25+CD4+ T cells: a autoimmunity," <i>J. Immunol.</i> 163:5211-5218 (1999).
flah, K., Gregoire, M., "Standardized generation of fully ed dendritic cells for clinical use," <i>Cancer Immunol</i>
ontgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. ell anergy: An early event in the course of tumor:1178-1183 (1998).
Powrie, "Human CD4(+)CD25(+) thymocytes and activity in vitro," Eur. J. Immunol. 31:1247-1254 (2001).
vach EM, "CD4+CD25+ T cells inhibit both the induction and represent a unique lineage of immunoregulatory cells,"
ch EM, "Pathogenesis of post-thymectomy autoimmune e triphosphatase-reactive T cells," <i>J. Immunol.</i> 157:1799-
A. van Elsas, T. N. Schumacher, M. E. Wildenberg, J. P. Ielief, "Synergism of cytotoxic T lymphocyte-associated regulatory T cells in antitumor therapy reveals alternative totoxic T lymphocyte responses," <i>J. Exp. Med.</i> 194:823-832
S., Rouse, B.T., "CD4+CD25+ T Cells regulate virus- esponses," <i>J Exp Med</i> 198(6):889-901 (2003).
mon, L. W. Poulter, and A. N. Akbar, "Human a highly differentiated and apoptosis-prone population,"

Examin	er Sig	nature: Date Considered:
	86.	Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA, "A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood," <i>J. Immunol.</i> 166:7282-7289 (2001).
	85.	Wood., K.J., Sakaguchi, S., "Regulatory T cells in transplantation tolerance," <i>Nat Rev Immunol</i> 3(3):199-210 (2003).
	84.	Woo, E. Y., C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, L. R. Kaiser, and C. H. June, "Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer," <i>Cancer Res.</i> 61:4766-4772 (2001).
	83.	Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW, "Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment," <i>Immunity</i> 3:521-530 (1995).
	82.	Wesselborg S, Janssen O, Kabelitz D, "Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells," <i>J. Immunol.</i> 150:4338-4345 (1993).
	81.	Walker, M.R., Kasprowicz, D.J., Gersuk, V.H., Benard, A., VanLandeghen, M., Buckner, J.H., Ziegler, S.F., "Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25+ T cells," <i>J Clin Invest</i> 112(9):1437-1443 (2003).
	80.	Vella AT, Dow S, Potter TA, Kappler J, Marrack P, "Cytokine-induced survival of activated T cells in vitro and in vivo," Proc. Natl. Acad. Sci. USA 95:3810-3815 (1998).
	79.	Trenado, A., Charlotte, F., Fisson, S., Yagello, M., Klatzmann, D., Salomon, B.L., Cohen, J.L., "Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-vesus-host disease while maintaining graft-versus-leukemia," <i>J Clin Invest</i> 112(11):1688-1696 (2003).
ŧ	78.	Thorstenson, K.M., Khoruts, A., "Generation of anergic and potentially immunorgulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen," <i>J Immunol</i> 167(1):188-195 (2001).
	77.	Thornton, A.M., Piccarillo, C.A., Shevach, E.M., "Activation requirements for the induction of CD4+CD25+ T cell suppressor function," <i>Eur J Immunol</i> 34(2):366-376 (2004).
	76.	Thornton AM, Shevach EM, "Suppressor effector function of CD4+CD25+ immunoregulatory T cells i antigen nonspecific," <i>J. Immunol.</i> 164:183-190 (2000).
	75.	Thornton AM, Shevach EM, "CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation <i>in vitro</i> by inhibiting interleukin 2 production," <i>J. Exp. Med.</i> 188:287-296 (1998).
	74.	Taylor, P.A., Lees, C.J., Blazar, B.R., "The infusion of <i>ex vivo</i> activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality," <i>Blood</i> 99(10):3493-3499 (2002).
	73.	Taylor PA, Noelle RJ, Blazar BR, "CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade," <i>J. Exp. Med.</i> 193:1311-1318 (2001).
	72.	Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S, "Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4," <i>J. Exp. Med.</i> 192:303-310 (2000).
•	71.	Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Sakaguchi S, "Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state," <i>Int. Immunol.</i> 10:1969-1980 (1998).

			ugh citation if not in cor	
			·	
			•	
		•		
:				
•				